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mana.gemcnt of patients with cl i f fercntiated thyroicl cancer is thc main topic of this
tl.r es is.
Chapter I  sivcs a short introdtrct ion in the :rnatomy arrd physiology of the thyroid
gland. Knowlegde abor-rt  he regulat ion of t l -ryroici  
€lrowth and the transforrnation into a
rr.ral ignant thyroid tur.nor is surnmarized. Thyroid tumors can be dividcd in several
histologic types, of which dif fercntiatcd thyroid carcinorna is the most common f irrm.
In r lost cl i f f i rentiatecl thvroicl crrncers three important f i .rnct ion:r l  fcaturcs of the normal
thvroid cel l  trre prescrved, trarnelv, thc abi l i tv to rcsponcl to thvroicl st imulat ing hormone
(l 'SH), the abi l i tv to accumtrlate iodide and the abi l i ty to secrete thyroglobr,r l in. - l 'hese
specif ic f i rnct ional fèatures are ut i l iz-ecl in the nratragemenr of p:rt ients with cl i fÈrentiated
tl-rvroicl  carcinonra.
ln chapter 2 argunrents for a gcnetic basis of dif ïerentiatecl thvroid carcinoma are
clescribecl.  
' l 'he 
argr-rments car-r be for-rncl in epiclenriological data, i tr  the occun'ence of
occult crrrcinom:rs, irr  the occurrcnce of r.r .rult i fbcal i ty of the tumor and in the r isl< factors
for turnor devcloprne nt. L.r approxirnately 57o of paticnts the cl i f fère nt iatcd thyloid crrncer
is clonrinantlv inheritcd. Exist ing knowleecle aLrout gerrnl ine mutations atrd sornatic
rnutat ions in cl i fFerentiatcd thyroid carcinoma is clescribed. ( lurrently, research into a
spcciÍ ' ic ger mlinc mrrtat ion as b:rsis fbr the clevelopment of farni l ial  dif lcrentiated thvroid
carcinonra has yielded inconclusive results. Several genes har.e already becn irnpl icated,
but no single locus hirs yet been identi Í lecl by l inkage analysis. l t  is hypothesizecl that
associrrt ior.r anrr lysis wil l  bc of nrore value in eltrcidating the genetic base of dif ferentiated
thyroicl cance r than l inkrrge anaiysis.
Chapter 3 givcs an ovcrview of the nranagcment of dif fcrentiated thyroid carcinorna in
elclerly paticnts. Approxinratcly 25Vo of the p:rticnts in which differcntiated thyroid cancer
is cl iasnosecl, is 60 years or oldcr. The prognosis of eiclerly patients is poor comp:rred to
yoLlnger prl t ients, bccause old patients nrore oftcn present with poor prognostic fè,rtures,
such as large tumors, fol l icular or Hi ir thle cel l  subtypes, extr ir thyroidal growth and ci ist irnt
metastases. Currcnt therapy cor.rsists o[ a total thyroidcctomy, i f  necessary combined
with a lymph nocie t l issection and [ol lowed by radioiocl inc ablat ion. I{acl ioiodine thcrapy
in el i ler ly paticnts rnccts spccif ic problems, conccrning thyroid hornrone withdrawal,
sicle cffccts of ' r ' l  and ntrrsing problems. Special attclrt ion is given to the usc of external
rac l io therapr . ,  chenro therapy  anc l  hormona l  therapy  in  c lder ly  pa t ien ts .  Ac ld i t iona l
trc2rtme nt of rcsiclual,  recurrent or nrctastat ic disease must be tai lorcd, accoldins to the
st,rge of the cl isease, and sfroLrlcl  not be cleniecl on the basis of chronological aee. t- i fèlong
trc:rtrnent rvi th suppressi ' , 'e thyroid hormone therapv cloes not lead to long-term side
eÍ}ècts at old ase.
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Because of the r:rr i t1, of dif ïèrentiated thyroid carcinoma and the high overal l  survival
rate , prospcctive rarrdomized studies adclressing issues of diagnosis, treatmcnt and fol low-
up, :rre hardly avir i lable. I t  is r,rnl ikely that such str.rcl ics wil l  becorne avai lable in the ncar
future. Instead, d:rta from large patierrt  cohort studics has to learn the cl iniciar.rs, rvhat is
the best way to treat patients with dif fèrentiated thyroid ca.rcinoma. In chapter 4 the
results are presentecl of a cohort of 504 patients with dif fere nt iated thyroid carcinoma,
referrcd to the Departrnent of Endocrinology of the Universitv Hospital ( lroningen fbr
treatment with racl ioiodine ove r the past 23 years. Al l  patients were init ial ly treated with
(near-) total thyroiclectomy alrd 97o/o of parients received rrr I ablation fbr resiciual thyroid
t issue. lr f l lcacy of ablat ion was checkecl af ier 3 months. ResidLral disease was treated in a
3  months  t rea tment  in te rva l  w i th  ' r '1 .  A  fb l low-up reg imen,  inc lud ing  annua l  phys ica l
examinatior.r and serum thyroglobul in nre:rsurements withor,rt  di:rgnostic " ' l  whole-body
scint igraphy, was usecl for p:rt ients in con-rplete rernission. Mean fol low-up was 9 years
(range: I  month - 2-3 years). ln 85% of patients ablat ion, checked after 3 months, was
successfir l  and ir-r 59%o of patierrts treatrnentwas complcted within 6 n.ror.rths after ini t ial
surgery .  A t l0year theovera l l s t r rv iva lwas877o.Recur renceoccur red in8 .5%ofpat ien ts .
Risk f lctors for recurrence were older agc at presentation, extrathyroicial growth and
fol l icular or Htirthle cel l  subtvpe. I t  wrrs concluded that the eff icacy of I  tr l  ablat ion in
patients with dif lèrcntiated thyroid carcinoma can bc successfir l ly checkcd already after
3 m o n t h s . ' f h e r e p o r t e d t r e a t n r e n t s t r a t c [ ï y w i t h a s h o r t r r r l  t r e a t m e n t i n t e r v a l s h o w s a
low recurrence rate and a hieh overal l  strr" ' ival rate. 
' fhese 
rcsults just i fy a fol low-up
regimen l irnited to annual phvsical exanrin:rt ion ancl serum thyroglobul in rneasuremcnts
f t r r  p : t t i e r r t s  i n  c c r r r r p l e t c  r e n t i s t i o t r .
In the l i tcrature considerable variat ions exist in the fbl low-up protocols fbr patients with
cl i f fercntiatcd thyroid carcinoma after ini t ial  treatment rvi th total thyroidecton'ry :rnd
radioiocl ine ablat ion. Most protocols rely on serial diagnostic 1'r l  imagir-rg and serun-r
thyroglobul in rneasurements. - l-he applicd diagnostic ' r ' I  doses vary betwccn 37 and 370
MBq. 13e tter lesion detectabi l i ty is obtained by higher diagnostic doses. ' l -he aim of the
studv, c' lcscribed in chapter 5 was to determine thc vield of a high-dose cl iagnostic scan
with 370 MBq 'r ' l  i r .r  patients with a negative low-close diagnostic scan with 74 MBq
lrrI .  I l .etrospective evaluation was perforn'red in l5U patients, who receivccl a high-close
diagnostic scan u' i th 370 Mllq rrr l  because of a negative low-close diagrrostic scan with
74 MBq 1r11 .  In  127 (80%)  o f  pa t ien ts  the  370 MBq ' r r l  scan w: rs  neg i l t i ve ,  s im i ia r  to  the
prececl irrg low-dosc, scan. ln 31 (20Vo) of patients abnorm:rl  r-rptake was present on the
370 M l lq diagnostic scan. In I  9 of thesc 31 patients scnrm thvroglobul in was trndetectable.
Spec ia l  a t ten t ion  rvas  pa ic l  to  the  pa t icn ts  w i th  pos i t i ve  h igh-dose d iagnos t ic  sc . r r rn iug
and undetectable serum thyroglobul in levels after thyroid hormone withdrawal. 'T'he
high-dose diagnostic scan wns fàlse posit ive in sevcn patients and sol i tary thyroicl bcd
uptake was seen in e ight patients. In on11, four paticnts (2.5olt) the high-close diagnostic
scans rcvealed relevant uptake caused Lry resiclual cl i f ferentiated thyroicl cancer. [ t  was
concltrclcd that in 97.5o/o of patients the 370 MBcl lrr l  diagnostic scan had no addit ional
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value over the combination of a low-dose diagnostic '3rI scan w1th74 MBq and a serum
thyroglobulin level measurement for correct clinical decision making whether the patient
requires additional 1311 therapy.
Management of patients with negative diagnostic radioiodine scanning and elevated
serum thyroglobulin levels, is a widely debated problem. lt is advocated to treat patients
with a negative 13rI diagnostic whole-body scan with an empirical therapeutic dose of
100 -300 mCi 13'I. However. the theraoeutic benefit of this treatment is not clear. The
aim of the study described in chapier 6 was to investigate the course of serum
thyroglobulin and ciinical outcome in patients with differentiated thyroid carcinoma,
negative diagnostic 'r'I scanning and elevated serum thyroglobulin levels during thyroid
hormone withdrawal, after treatment with the so-called "biind treatment" with high-
dose rrll therapy. We identified 56 patients in the above mentioned cohort of 504 patients,
who were treated with a blind therapeutic dose of 150 mCi 13r1. Median follow-up from
the blind therapeutic dose unti l end of observation was 4.2years (range: 0.5 -13.5 years).
Among the 56 blindly treated patients, 28 patients showed uptake at the posttherapy
whole-body scan and 28 patients had a negative posttherapy whole-body scan. No
differences between both groups were found in change of serum Tg before and after
blind treatment. During follow-up 18 patients of the 2B patients with a positive
post therapywhole-bodyscanachievedremiss ioncomparedto l0of the28pat ientswi th
a negative posftherapy whole-body scan (P=0.06). In the negative posttherapy whole-
body scan group nine patients died because of their disease and none in the negative
posttherapy group. 'I-his led to a different 5-years survival between both groups (P=0.001)
with a Lretter overall survival in the positive posttherapy group. It is likely that a better
functional diffèrentiation of the tumot which is reflected by a positive posttherapywhole-
body scan, is the main reason for the favorable prognosis in these patients.
Chapter 7 gives a short report of the first experience in the University Hospital Groningen
of the use of rEF-fluoro-2-deoxy-D-glucose (F'DG)-positron emission tomography (PET)
scanning as a new diagnostic modality in differentiated thyroid cancer patients. FDG-
PET was performed in 11 patients with diffèrentiated thyroid carcinoma who all had
undergone total thyroidectomy and r3rI ablation therapy and in whom serum thyro-
globulin (median 9.7 ngl ml) during suppression therapy with thyroxin, remained
de tectable, despite a negative whole-body scan with 150 mCi rrrI. In all patients F'DG-
PET was read as positive. However, in seven of 1 1 patients (640/o) other imaging techniques
found no anatomical substrate and the FDG-PET was interpreted as false positive. Most
of the false positive locations were considered to be cervical and thoracic lymph nodes. A
change in clinical management directed by FDG-PET was made in only one patient
(9%). Caution is suggested in the interpretation of abnormal uptake of FDG.
'fhe influence ofTSH stirnulation on the accumulation of FDG in persibrenr, ccurrenr
or mctastatic differentiatecl thyroid carcinoma is studied in chapter 8. Tl're accumulation
of I r r I ,  needed













































































of 'rrl, needed for diagnostic rrl l  scanning, is much bettcr duringTSH stimulation. This
is attained by thyroid hormone withdrawal and leads to hypothyroidism. Eight patients
underwent both a FDG-PE'f scan during thyroid hormone suppression therapy and
after thyroid hormone withdrawal. AFter the second F'DG-PET scan, a therapeutic r:rrI
dose was aclministered with post-therapy scans obtained 10 days later. Findinss were
verif ied using other imaging modalit ies or biopsies. The FDG-PET sc:rns during TSH
suppression showed abnormalit ies in four patients and the FDG-PET scan during TSH
stimulation in five patients. One patient showed only a positive FDG-PET scan during
TSH stimulation. In rwo other patients the FDG-PET scan during TSH stimulation
clearly identif ied more lesions, ancl in all positive patients lesion contrast was better
during TSH stimulation. In two patients FDG-PET findings during TSF{ stimulation
led to a change in clinical management. It is concluded that the performance of FDG-
PET during TSH stimulation was either superior or equal to FDG-PEI- during TSH
suppression, but never inferior.
The outcome of patients with bone metastases of diÍIerentiated thyroid carcinoma is
worse compared to the overall prognosis of patients with differentiated thyroid carcinoma.
In chapter 9 the results of embolizationr as a new therapeutic approach for patients with
large bone ffretastases, are described. Five symptomatic patients, who presented with a
large unresectable bone metastasis of differentiated thyroid carcinoma were treated with
radioiodine and embolization. The eflèct of this combined treatment was comDared to
the effect of radioiodine without embolization in a historical control group of six patients.
Serum thyroglobulin levels, pain and neurological symptoms were scored. Both groups
were treated similar with total thyroidectomy followed by ablation with 5.6 GBq (= 150
mCi)  '3r I  and a second dose of  5.6 GBqrr l l  three months la ter ,  except  for  embol izat ion
in the embolization group, which took place berween the two radioiodine treatments.
Radioiodine therapy with or without additional embolization resulted in a rapid relief of
pa in  and  neu ro log i ca l  symp toms .  Howeve r ,  i n  t he  embo l i za t i on  g roup  se rum
thyroglobulin at the secondrrrl therapy had decreasedlly 88.7o/o, which was moÍe
compared to the decrease of serum thyroglobulin in the control group (18.6%). CT-
scanning showed a median volume reduction of the metastasis after radioiodine treatment
combined with embolization of 52.5%. Embolization was not accompanied with severe
complications and was well tolerated.'I 'his preliminary study suggests that embolization
of bone merastases of differentiated thyroid carcinoma in combination with radioiodine
treatment results in a better init ial recluction of serum thvroelobulin level compared to
raclioiodine treatment alone.
In chapter l0 a piiot study in seven patients is described in which marimastat is added to
embolization in the treatment of bone metastases. Marimastat is an inhibitor of matrix
metalloproteinases. These matrix metalloproteinases are required for :rrrgiogenesis. All
seven patients unde rwent total thyroidectomy, radioiodine therirpy and ernbolization of
bone metastases. Six patients discontinued marimastat therapy after a median of 12
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weeks, four because of tumor progression, two because of severe mllsculoskeletal
symptoms. ln one patient the bone metastasis showed regression after marimastat
combined with embolization. I t  was concluded that the addit ior-r of marimastat to
embolization had no clear beneficia. l  effects. In addit iorr,  musculoskeletal adverse effects
proved to be a serious drawback.
FUTURE PERSPECTIVES
Differentiated thyroid cancer is a rarc disease with a favorable prognosis. There is, however,
a strikirrg dif lèrence between 10-years overall survival and disease-free survival (87o/o vs.
69%) (chapter 4). This implies that most patients are cured after init ial therapy with
surgery and radioiodine. However, a considerable percentage of patients l ive for many
years with persistent clisease. A smaller part of these patients have more aggressive disease
and dye rather soon r.rfter cliagnosis. Only a small percentage of patients have recurrenr
disease afier con.rplete remission.'fhe treatment and follow-up strategies for tl'rese diFfèrent
patient categories ti l l  need improvement. \We have shown in chapter 4 that a l imitecl
regimer-r for iong-term fbllow-up is lustif ied for patients in con.rplete remission. However,
it is im;rortant to m:rintain detailed databases f 'or long-term foilow-up, also of these
patients in con'rplete remissiotr. Canccr survivorship research mtrst monitor late recurrences,
late mortirl i ty, late toxicity rclated to the init ial therapy or thyroid hormonc suppressivc
tl.rerapy, seconcl neoplasms, ctcetera. This nray also result in the identif ication of :rdverse
eflècts in cert:rin subpopulations (e.g. chilcleren, elderly, fèrnales in childbaring age) and
ir.r the developnrent of effcctive prevention or intervention srrategics. Lifè-long fbllow-
u1.r is thu.s neccessary. -[ 'his inrplies that a large number of dif]èrentiared thyroid cancer
sttrvivors has to bc followed in the firture. An increasing role firr regional hospitals besides
spccializcd centcrs is to be expectecl in monitoring thcse patients. The refole, the patients
shor.rld visit the specialized cncocrinc cancer cenrre fcrr example evcry five years.
Thc cxploration of new, perhaps morc intense, cliagnostic or treatment procedures
is jr.rstif iecl fbr patients with persiste nt disease and paticnts with a high ri.sk firr recllrrencc.
Future rcsearch shor-rlcl especiar.l ly fbcus on thesc paticrrr carcrtories wirh a lcss fàvorablc
prognosis. Improveme Irt in thc understanding of the biology and generics of cliffercntiated
thyroid carcinonra may lead to new therapeutic targets :rnd approaches. This research is
an opportunity fbr enrploying interdisciplinaily collaboration berwecn endocrinologists,
oncologists, nuclear physicians, cpidemiologists ancl !ïenericisrs in ancl outsic{c The
Nctl 're rlrrncls.
Tïeatment protocol
' l 'he 
results of thc stuclics described in chapters 4,5 ancl6, have alreacly been incor;rorarecl
into a reviscd trcatne nt ar.rcl fbllow-up protocol f irr patients rvith dilÈrentiated th1'roicl
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